Drugs used to treat HIV also reduce risk of HIV infection, review suggests. People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Antiretroviral therapy (ART) is the standard drug treatment for HIV in patients whose disease has progressed to a certain level. Antiretroviral drugs are also beginning to be used as prophylactics in people at high risk of acquiring the disease from sexual partners. The use of antiretroviral drugs in preventing as opposed to treating HIV infection is referred to as pre-exposure prophylaxis (PrEP). Natural HIV control may rely on sequence of T cell receptor protein. Natural HIV control may rely on sequence of T cell receptor protein Protein on the surface of killer T cells appears to confer ability to suppress viral replication 10/Jun/2012 The rare ability of some individuals to control HIV infection with their immune system alone appears to depend – at least partially – on specific qualities of the immune system's killer T cells and not on how many of those cells are produced. In a Nature Immunology paper that has received advance online publication, researchers at the Ragon Institute of Massachusetts General Hospital, MIT and Harvard report that – even among individuals sharing a protective version of an important immune system molecule – the ability of HIV-specific killer T cells to control viral replication appears to depend on the particular sequence of the protein that recognizes HIV infected cells.
"A big remaining question is why these particularly effective killer cells are generated in some people but not in others. Newly discovered breast milk antibodies help neutralize HIV. Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, and showed that the B cells in breast milk can generate neutralizing antibodies that may inhibit the virus that causes AIDS. HIV-1 can be transmitted from mother to child via breastfeeding, posing a challenge for safe infant feeding practices in areas of high HIV-1 prevalence.
But only one in 10 HIV-infected nursing mothers is known to pass the virus to their infants. "That is remarkable, because nursing children are exposed multiple times each day during their first year of life," said senior author Sallie Permar, M.D., Ph.D., an assistant professor of pediatrics and infectious diseases at Duke. The study was published on May 18 in PLoS One, an open-access journal published by the Public Library of Science. The study itself wasn't easy to perform, she noted. Study using stem cell therapy shows promise in fight against HIV.
Marijuana-like chemicals inhibit human immunodeficiency virus (HIV) in late-state AIDS. Mount Sinai School of Medicine researchers have discovered that marijuana-like chemicals trigger receptors on human immune cells that can directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS, according to new findings published online in the journal PLoS ONE. Medical marijuana is prescribed to treat pain, debilitating weight loss and appetite suppression, side effects that are common in advanced AIDS.
This is the first study to reveal how the marijuana receptors found on immune cells -- called cannabinoid receptors CB1 and CB2 -- can influence the spread of the virus. Understanding the effect of these receptors on the virus could help scientists develop new drugs to slow the progression of AIDS. HIV infects active immune cells that carry the viral receptor CD4, which makes these cells unable to fight off the infection. In order to spread, the virus requires that "resting" immune cells be activated. Funding for this study was provided to Drs. New HIV-vaccine tested on people shows limited success. Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers.
The participants were so to say vaccinated with their own cells. The researchers filtered certain white blood cells out of the volunteer's blood, 'loaded' them outside the body and then gave them back. The immune system of the testees was better than before in attacking and suppressing the virus, the scientists reported in the journal AIDS. But they still cannot cure the disease. Actually, medical science can control an HIV-infection quite well, with a medicine cocktail. 'Seropositive' people (people who are infected with the HIV virus) now can lead a reasonably normal life, but their virus is not exterminated. The virologists and HIV-physicians of the Institute of Tropical Medicine and the haematologists of Antwerp University Hospital have cooperated for years on that problem.
Indiana University Scientist Works to Detach Protein that HIV Uses as Protective Shield. February 13, 2012 INDIANAPOLIS -- One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus’ ability to evade the body’s immune system. Now an Indiana University researcher is testing a compound developed by a Harvard University colleague that could help put the immune system back in the hunt. It’s not that the human immune system doesn’t recognize HIV. Indeed, an infection causes the body to unleash antibodies that attack the virus, and initially some HIV is destroyed. But HIV is able to quickly defend itself by co-opting a part of the innate human immune system — the immune system people are born with, called the complement. The complement includes a vital mechanism that prevents immune system cells from attacking the body’s own cells.
“HIV is very clever. In November, the Bill & Melinda Gates Foundation announced it had awarded nine new Grand Challenges Explorations Phase II grants, one of them to Dr. Related Articles. How a protein protects cells from HIV infection. A novel discovery by researchers at NYU Langone Medical Center and colleagues reveals a mechanism by which the immune system tries to halt the spread of HIV. Harnessing this mechanism may open up new paths for therapeutic research aimed at slowing the virus' progression to AIDS. The study was published online ahead of print on February 12 in Nature Immunology. "A lot of research on viruses, especially HIV, is aimed at trying to understand what the body's mechanisms of resistance are and then to understand how the virus has gotten around these mechanisms," said co-lead investigator Nathaniel R. Landau, PhD, a professor of microbiology at the Joan and Joel Smilow Research Center at NYU School of Medicine.
The research focused on a protein called SAMHD1. Dr. When a virus, like HIV, infects a cell, it hijacks the cell's molecular material to replicate. Researchers wanted to understand how cells containing the SAMHD1 protein are protected from such hijacking. Starve a Virus, Feed a Cure? New Findings Show How Some Cells Protect Themselves against HIV February 12, 2012 Baek Kim and Waaqo Daddacha in Kim’s laboratory. Their ability to make precise measurements of DNA’s building blocks helped them discover why HIV-1 does not infect certain white blood cells. A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online in Nature Immunology.
The finding comes from an international team of researchers including scientists from the University of Rochester Medical Center, NYU Langone Medical Center, several institutions in France – and a graduate student who is a political refugee from Africa and is now at work in a Rochester laboratory, intent on helping his people who have been devastated by the HIV epidemic. “It makes sense that a mechanism like this is active in macrophages,” said Kim. Unpicking HIV’s invisibility cloak. Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel target—its camouflage coat. HIV hides inside a cloak unusually rich in a sugar called mannose, which it uses to slip past the immune system before infecting its host’s cells. Recently, however, biochemists discovered a family of chemical compounds that stick strongly to mannose.
Understanding how this mechanism works could reveal a way to make drugs adhere to and kill HIV. Yu Nakagawa and Yukishige Ito at the RIKEN Advanced Science Institute in Wako and their colleagues from several research institutes in Japan are leading the effort: they have mapped the binding site of the mannose-binding compound pradimicin A1. Mannose-binding compounds are particularly attractive to drug researchers thanks to their double-action anti-HIV effect. Unraveling just how pradimicin A recognizes mannose, however, has proven surprisingly difficult. Drug to Treat HIV in Children Shows Promise. Females may be more susceptible to infection during ovulation. A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection. Specifically, researchers from Spain and Austria found that women are most susceptible to infection, such as Candida albicans or other sexually transmitted diseases, during ovulation than at any other time during the reproductive cycle.
This natural "dip" in immunity may be to allow spermatozoa to survive the threat of an immune response so it may fertilize an egg successfully. "This could be an explanation why during ovulation females have more risk of being infected with sexual transmitted diseases like HIV or HPV," said Miguel Relloso, Ph.D., a researcher involved in the work from the Laboratorio de Inmunobiología Molecular at the Hospital Gregorio Marañón and Complutense University in Madrid, Spain.